Each has a bright long-term outlook, so they make excellent stocks to buy and hold.

The trade deal between the U.S. and the European Union could hit the pharmaceutical industry with billions in new costs and ultimately drive up prices and limit access. Why it matters: Drugmakers have ...

Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's GLP-1 drugs may have more potential, but Novo Nordisk is still likely to ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a ...

Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Novo Nordisk A/S (NVO) and Thermo Fisher Scientific Inc. (TMO), as well a micro-cap stock FONAR ...

On June 23, Novo Nordisk A/S (NYSE:NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has given a positive opinion to update the Ozempic label.

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to controversial practices around the sale of compounded drugs.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), Novo Nordisk A/S ...

If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage.